|+1 404 474 4654|
|+1 888 205 9894 (TF)|
C-rel (NfkB) (C-Term, Asp504) Peptide
|3 references available|
|Price||49.50 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Characteristics||Blocking peptide for C-rel (NFkB) (C-term D504) antibody ABIN390315|
|Specificity||The synthetic peptide sequence used to generate the antibody AP6336b was selected from the NFkB region of human C-rel (NFkB) (C-term D504). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
Background: Nuclear factor (NF)-kappa B is a sequence specific transcriptional activator that binds to the intronic enhancer of kappa light chain gene in B lymphocytes. NF-kB regulates the expression of a wide variety of genes that involved in apoptosis, viral life cycle, tumorigenesis, autoimmune diseases and inflammation. NF-kB is a heterodimer of members of the rel family of proteins such as p50, p65, and c-rel. In most cells, inhibitory IkB proteins sequester NF-kB/Rel in the cytoplasm. Cellular stimulation precipitates degradation of IkB and modification of NF-kB/Rel proteins, permitting translocation of NF-kB/Rel (c-Rel and RelA) to the nucleus for action on target genes. The important role of c-Rel in B-cell development, growth, and survival has been intensively studied, as well as its function in differentiation and lymphopoiesis (particularly lymphoid cancer).
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles|
|Restrictions||For Research Use only|
Bernard, Gosselin, Monte et al.: "Involvement of Rel/nuclear factor-kappaB transcription factors in keratinocyte senescence." in: Cancer research, Vol. 64, Issue 2, pp. 472-81, 2004 (PubMed).
Phelps, Ghosh: "Discreet mutations from c-Rel to v-Rel alter kappaB DNA recognition, IkappaBalpha binding, and dimerization: implications for v-Rel oncogenicity." in: Oncogene, Vol. 23, Issue 6, pp. 1229-38, 2004 (PubMed).
Jain, Ma, Lopez-Granados et al.: "Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation." in: The Journal of clinical investigation, Vol. 114, Issue 11, pp. 1593-602, 2004 (PubMed).